Difference between revisions of "Team:BIT/Design/Biosenor"
LIULINSHAN (Talk | contribs) |
LIULINSHAN (Talk | contribs) |
||
| Line 92: | Line 92: | ||
<a href="https://2017.igem.org/Team:BIT/Team">Team</a> | <a href="https://2017.igem.org/Team:BIT/Team">Team</a> | ||
<ul class="dropdown"> | <ul class="dropdown"> | ||
| − | <li><a href="https://2017.igem.org/Team:BIT/ | + | <li><a href="https://2017.igem.org/Team:BIT/Collaborations">Collaborations</a></li> |
<li><a href="https://2017.igem.org/Team:BIT/Team/Member">Member</a></li> | <li><a href="https://2017.igem.org/Team:BIT/Team/Member">Member</a></li> | ||
<li><a href="https://2017.igem.org/Team:BIT/Attributions">Attributions</a></li> | <li><a href="https://2017.igem.org/Team:BIT/Attributions">Attributions</a></li> | ||
Revision as of 16:44, 1 November 2017
Abstract
Cancer is one of the three major killers that threatened mankind since the 21st century. The reason is that it is not taken seriously at the beginning of cancer until it is detected in the middle and late stages, resulting in a very low cure rate. Therefore, early detection becomes a decisive factor to improve the cure rate of cancer. In this project, we use alpha-fetoprotein (AFP)as an example, using the factor that AFP can specifically bind to the aptamer, to achieve a signal conversion that using a small molecule (lysine) to replace AFP content in serum, just like equivalent substitutions in mathematics, to achieve the early detection of liver cancer. This system can be extended to all of the disease detection, which use protein as biomarkers.
